PTEN mutation-targeting drugs currently in clinical trials include VOX101, and the small molecule UCL-TRO-1938, a PI3K activator upstream of PTEN, has recently been found to promote neural regeneration in neurons after a stroke or some ischemia-reperfusion injury (Gong et al., 2023). Here, PTEN is linked to Stroke.